Minerva Surgical (NASDAQ:UTRS) Downgraded by Zacks Investment Research to “Sell”

Zacks Investment Research cut shares of Minerva Surgical (NASDAQ:UTRSGet Rating) from a hold rating to a sell rating in a report released on Wednesday morning, Zacks.com reports.

According to Zacks, “Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. Minerva Surgical is based in SANTA CLARA, Calif. “

Separately, Piper Sandler dropped their price objective on shares of Minerva Surgical from $12.00 to $6.00 in a research note on Thursday, May 12th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Minerva Surgical presently has a consensus rating of Buy and a consensus target price of $10.50.

NASDAQ UTRS opened at $2.58 on Wednesday. Minerva Surgical has a 12 month low of $1.61 and a 12 month high of $10.37. The company has a 50-day moving average of $3.73 and a 200-day moving average of $5.09. The company has a quick ratio of 1.72, a current ratio of 2.32 and a debt-to-equity ratio of 1.13.

Minerva Surgical (NASDAQ:UTRSGet Rating) last posted its quarterly earnings data on Wednesday, May 11th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.07). On average, sell-side analysts forecast that Minerva Surgical will post -1.24 EPS for the current year.

Several large investors have recently modified their holdings of UTRS. Virtu Financial LLC purchased a new stake in shares of Minerva Surgical during the 4th quarter worth about $54,000. Renaissance Technologies LLC purchased a new position in Minerva Surgical in the 4th quarter worth approximately $78,000. BlackRock Inc. purchased a new position in Minerva Surgical in the 4th quarter worth approximately $88,000. Millennium Management LLC purchased a new position in Minerva Surgical in the 4th quarter worth approximately $134,000. Finally, Ghisallo Capital Management LLC purchased a new position in Minerva Surgical in the 4th quarter worth approximately $386,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

About Minerva Surgical (Get Rating)

Minerva Surgical, Inc, a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps.

Read More

Get a free copy of the Zacks research report on Minerva Surgical (UTRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Minerva Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Surgical and related companies with MarketBeat.com's FREE daily email newsletter.